DK1015587T3 - DcR3 polypeptid, en TNFR-homolog - Google Patents

DcR3 polypeptid, en TNFR-homolog

Info

Publication number
DK1015587T3
DK1015587T3 DK98948386T DK98948386T DK1015587T3 DK 1015587 T3 DK1015587 T3 DK 1015587T3 DK 98948386 T DK98948386 T DK 98948386T DK 98948386 T DK98948386 T DK 98948386T DK 1015587 T3 DK1015587 T3 DK 1015587T3
Authority
DK
Denmark
Prior art keywords
dcr3
tnfr
homolog
dcr3 polypeptide
tnfr homolog
Prior art date
Application number
DK98948386T
Other languages
English (en)
Inventor
Daniel B Tumas
William I Wood
Audrey Goddard
Avi J Ashkenazi
David Botstein
Austin L Gurney
Kyung Jin Kim
David A Lawrence
Robert Pitti
Kelly H Dodge
Margaret A Roy
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1015587T3 publication Critical patent/DK1015587T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Polymerization Catalysts (AREA)
DK98948386T 1997-09-18 1998-09-18 DcR3 polypeptid, en TNFR-homolog DK1015587T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5928897P 1997-09-18 1997-09-18
US9464098P 1998-07-30 1998-07-30
PCT/US1998/019661 WO1999014330A1 (en) 1997-09-18 1998-09-18 DcR3 POLYPEPTIDE, A TNFR HOMOLOG

Publications (1)

Publication Number Publication Date
DK1015587T3 true DK1015587T3 (da) 2008-08-25

Family

ID=26738582

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98948386T DK1015587T3 (da) 1997-09-18 1998-09-18 DcR3 polypeptid, en TNFR-homolog

Country Status (13)

Country Link
US (5) US6764679B2 (da)
EP (1) EP1015587B1 (da)
JP (2) JP4303883B2 (da)
AT (1) ATE393222T1 (da)
AU (2) AU762959B2 (da)
CA (1) CA2303225C (da)
CY (1) CY1108175T1 (da)
DE (1) DE69839401T2 (da)
DK (1) DK1015587T3 (da)
ES (1) ES2306480T3 (da)
IL (3) IL134578A0 (da)
PT (1) PT1015587E (da)
WO (1) WO1999014330A1 (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
WO2000053755A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of tumor
US20040013664A1 (en) * 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
CN1247567A (zh) 1997-01-14 2000-03-15 人体基因组科学有限公司 肿瘤坏死因子受体6α和6β
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
DK1015587T3 (da) 1997-09-18 2008-08-25 Genentech Inc DcR3 polypeptid, en TNFR-homolog
WO1999031128A2 (en) * 1997-12-16 1999-06-24 Incyte Pharmaceuticals, Inc. Human tumor necrosis factor-r2-like proteins
DE19809978A1 (de) * 1998-03-09 1999-09-16 Basf Ag Neuer Rezeptor aus der menschlichen Lunge
HUP0102067A2 (hu) * 1998-03-30 2001-10-28 Eli Lilly And Co. A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai
AU2211100A (en) * 1998-12-22 2000-07-12 Eli Lilly And Company Therapeutic applications of flint polypeptides
BR0007556A (pt) 1999-01-15 2001-10-23 Biogen Inc Antagonistas de tweak e de receptor de tweak e uso dos mesmos para tratar distúrbios imunológicos
NZ513294A (en) * 1999-03-04 2004-04-30 Human Genome Sciences Inc Tumor necrosis factor receptors 6alpha and 6beta
US6965012B1 (en) 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
EP1165780A2 (en) * 1999-03-30 2002-01-02 Eli Lilly And Company Flint polypeptide analogs
US6835814B1 (en) 1999-03-30 2004-12-28 Eli Lilly And Company Protease resistant flint analogs
DE60036199T2 (de) * 1999-03-30 2008-05-21 Eli Lilly And Co., Indianapolis Proteaseresistente flint-analoge
AU2215300A (en) * 1999-06-02 2000-12-28 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
US6521422B1 (en) 1999-08-04 2003-02-18 Amgen Inc. Fhm, a novel member of the TNF ligand supergene family
AU7053000A (en) * 1999-09-10 2001-04-10 Eli Lilly And Company Flint compounds and formulations thereof
WO2001018055A1 (en) * 1999-09-10 2001-03-15 Eli Lilly And Company Flint analog compounds and formulations thereof
AU1915201A (en) * 1999-12-07 2001-06-18 Eli Lilly And Company Improving stability of flint through o-linked glycosylation
EP1272647B1 (en) 2000-04-11 2014-11-12 Genentech, Inc. Multivalent antibodies and uses therefor
WO2001085193A2 (en) * 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization using a tweak agonist and an angiogenic factor
WO2002018622A2 (en) * 2000-08-25 2002-03-07 Human Genome Sciences, Inc. TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
US7208151B2 (en) * 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
WO2002060949A2 (en) * 2001-02-01 2002-08-08 Eli Lilly And Company Glycoforms a fas ligand inhibitory protein analog
CN103536916B (zh) 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
US20030055221A1 (en) * 2002-05-07 2003-03-20 Jirong Lu Stability of flint through o-linked glycosylation
EP1447093A1 (en) 2003-02-14 2004-08-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries
EP1859277A4 (en) 2005-02-17 2010-03-17 Biogen Idec Inc TREATMENT OF NEUROLOGICAL DISORDERS
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20090269345A1 (en) * 2005-12-23 2009-10-29 Rong Fan CLN248 Antibody Compositions and Methods of Use
ES2420582T3 (es) 2006-12-28 2013-08-26 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts La neutralización de la actividad de CD95 bloquea la invasión de células de glioblastoma in vivo
PL3903829T3 (pl) 2009-02-13 2023-08-14 Immunomedics, Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
WO2011068845A1 (en) 2009-12-02 2011-06-09 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
WO2014013036A1 (en) 2012-07-18 2014-01-23 Apogenix Gmbh Inhibitors of the cd95 signaling pathway for treatment of mds
EP2885002A4 (en) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
EP3954373A1 (en) 2014-10-07 2022-02-16 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
EP3076179A1 (en) 2015-03-30 2016-10-05 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Diagnosis and treatment of low grade gliomas
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
EP3313443B9 (en) 2015-06-25 2023-10-04 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP4056232A4 (en) * 2019-09-13 2023-09-13 Kyowa Kirin Co., Ltd. DCR3 VARIANT
WO2021108727A1 (en) 2019-11-27 2021-06-03 Myst Therapeutics, Inc. Method of producing tumor-reactive t cell composition using modulatory agents
JPWO2022239720A1 (da) 2021-05-10 2022-11-17

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
DE3889546T2 (de) 1987-12-21 1994-09-08 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO2000053758A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2000032221A2 (en) 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
CN1247567A (zh) * 1997-01-14 2000-03-15 人体基因组科学有限公司 肿瘤坏死因子受体6α和6β
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
DE69837806T3 (de) 1997-01-28 2012-01-05 Human Genome Sciences, Inc. "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
US5885800A (en) 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
EP1019502A2 (en) 1997-08-06 2000-07-19 Regeneron Pharmaceuticals, Inc. Human orphan receptor ntr-1
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
DK1015587T3 (da) * 1997-09-18 2008-08-25 Genentech Inc DcR3 polypeptid, en TNFR-homolog
WO1999026977A1 (en) 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2
WO1999031128A2 (en) 1997-12-16 1999-06-24 Incyte Pharmaceuticals, Inc. Human tumor necrosis factor-r2-like proteins
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
DE19809978A1 (de) 1998-03-09 1999-09-16 Basf Ag Neuer Rezeptor aus der menschlichen Lunge
HUP0102067A2 (hu) 1998-03-30 2001-10-28 Eli Lilly And Co. A TNF receptorcsaládba tartozó érett FLINT (mFLINT) polipeptid vagy más néven az OPG3 terápiás alkalmazásai
NZ513294A (en) 1999-03-04 2004-04-30 Human Genome Sciences Inc Tumor necrosis factor receptors 6alpha and 6beta
EP1165780A2 (en) 1999-03-30 2002-01-02 Eli Lilly And Company Flint polypeptide analogs
DE60036199T2 (de) 1999-03-30 2008-05-21 Eli Lilly And Co., Indianapolis Proteaseresistente flint-analoge
AU6517800A (en) * 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
TW528801B (en) 2000-12-05 2003-04-21 Anawrahta Biotech Co Ltd Monoclonal antibodies for the detection of decoy receptor 3, hybridomas producing said antibodies and uses thereof
CN102786631B (zh) * 2012-08-16 2014-05-14 京东方科技集团股份有限公司 光敏性碱可溶性树脂、其制备方法及彩色光刻胶

Also Published As

Publication number Publication date
US20020065210A1 (en) 2002-05-30
IL134578A0 (en) 2001-04-30
CA2303225C (en) 2015-03-31
CY1108175T1 (el) 2014-02-12
US20100080793A1 (en) 2010-04-01
JP2001516581A (ja) 2001-10-02
WO1999014330A1 (en) 1999-03-25
DE69839401T2 (de) 2009-05-07
PT1015587E (pt) 2008-07-31
AU9497098A (en) 1999-04-05
US20040175791A1 (en) 2004-09-09
ATE393222T1 (de) 2008-05-15
AU2003252913A1 (en) 2003-11-06
IL193919A0 (en) 2009-05-04
IL134578A (en) 2010-06-16
CA2303225A1 (en) 1999-03-25
US6764679B2 (en) 2004-07-20
ES2306480T3 (es) 2008-11-01
WO1999014330A8 (en) 1999-05-27
JP4303883B2 (ja) 2009-07-29
US20020061559A1 (en) 2002-05-23
JP2009159970A (ja) 2009-07-23
DE69839401D1 (en) 2008-06-05
EP1015587A1 (en) 2000-07-05
EP1015587B1 (en) 2008-04-23
US20040014176A1 (en) 2004-01-22
AU762959B2 (en) 2003-07-10
JP5153679B2 (ja) 2013-02-27

Similar Documents

Publication Publication Date Title
DK1015587T3 (da) DcR3 polypeptid, en TNFR-homolog
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
ATE196164T1 (de) Gereinigte scytalidium lacassen und nukleinsäuren dafür kodierend
DE69833784D1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
DK0981618T4 (da) Anti-Apo-2-antistof
DK368588A (da) Bindingsmolekyler med en enkelt polypeptidkaede
DE60033138D1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
IL193886A0 (en) Antibodies that bind to ldcam sequences
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
ATE358725T1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
ATE384787T1 (de) Tripeptidyl-aminopeptidase
DE69840631D1 (de) Apo-3 ligand
DK1009817T3 (da) RTD-receptor
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
FI971276A (fi) Lerk-6:ksi nimetty sytokiini
IL129139A0 (en) Vertebrate smoothened proteins
DE60026049D1 (de) POLYPEPTIDE MIT GLUCANOTRANSFERASE AKTIVITÄT UND DAFüR KODIERENDE NUKLEINSÄUREN
ATE309371T1 (de) Protein mit dnase-aktivität
ATE351909T1 (de) Neue peptidfragmente zur reinigung von proteinen
ATE408687T1 (de) Semaphorin polypeptide